Biogen contact information
225 Binney Street
Cambridge, MA 02142
(Europe & Canada)
Biogen International GmbH
Media and investors contacts
Patient safety is our highest priority and we are committed to completing timely evaluation of benefits and risks of our therapies and communicating this information to help healthcare professionals and patients make informed treatment choices.
Biogen has an ethical and regulatory responsibility to continually assess and communicate the benefit/risk profile of our products to patients, healthcare professionals and regulators.
On an ongoing basis, we collect information regarding adverse events and other safety information from patients, caregivers and healthcare professionals, among others. Additionally, in some instances, we conduct post-marketing studies to evaluate therapies’ long-term effects.
Our safety and benefit risk management team reviews safety information received from all sources (foreign, domestic, clinical trials, published literature, post-marketing) for our products and determines what actions, if any, may need to be taken regarding any potential evolving safety profile of our products.
When a potential safety issue is identified, we seek information to better understand the issue and we report our findings to applicable regulatory agencies. We also communicate newly identified product safety information to healthcare professionals and patients by updating the product labelling and providing other communications, as appropriate.
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard, or search for MHRA Yellow Card or in the Google Play or Apple App Store (UK) or www.hpra.ie or by email to firstname.lastname@example.org (Ireland). By reporting side effects, you can help provide more information on the safety of this medicine.
Biogen UK and Ireland contact details:
For neuroscience products UK 0800 008 7401 | IRE 1800 812 719 | Email: MedInfoUKI@biogen.com
For biosimilar products UK 0203 608 8622 | IRE 01 513 33 33 | Email: Medinfo.email@example.com
Note: Biogen markets Biosimilar products pursuant to an agreement with Samsung Bioepis, the marketing authorization holder for such products. If you report an Adverse Event (AE) / Product Complaint (PC) for any of these products, your report will be sent to Samsung Bioepis, who may follow-up with you if they require further information regarding your AE or PC.
If you wish to report any compliance concerns regarding Biogen or any of its employees or contractors, you may do so in writing at the address provided below or confidentially and anonymously, by using the Compliance Helpline.
To submit a report through the Compliance Helpline, click here for international Compliance Helpline dial-in numbers.
Click here to submit a report online, or write to us at:
Biogen International GmbH
Biogen-119410 V3 Date of Preparation: June 2023